metaPreg - Carbimazole, Thiamazole (Methimazole) during pregnancy

Carbimazole, Thiamazole (Methimazole)

Table Graphic exposition period:

Adverse outcome	Verdict	OR 95%CI	I2	k	No. cases	No. exposed	publication bias
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)		1.41 [1.14, 1.74]	28%	12 studies	249,105	4,750	low
Major congenital malformations		1.85 [1.20, 2.85]	9%	6 studies	134	1,846	serious
Genital anomalies		1.11 [0.75, 1.63]	0%	3 studies	25,766	2,856	not evaluable
Respiratory system anomalies		1.62 [1.11, 2.37]	0%	3 studies	15,998	2,856	not evaluable
Urinary malformations		1.69 [1.08, 2.67]	0%	3 studies	17,645	2,856	not evaluable
Carbimazole embryopathy		14.62 [10.40, 20.55]	0%	6 studies	2,316	4,301	not evaluable
Eye defects		2.38 [1.21, 4.71]	0%	2 studies	2,493	1,736	not evaluable
Congenital heart defects		1.73 [1.40, 2.15]	0%	3 studies	77,405	2,856	not evaluable
Limb defects		0.85 [0.65, 1.12]	0%	3 studies	74,533	2,856	not evaluable
Digestive system anomalies		2.99 [2.05, 4.36]	0%	3 studies	15,273	2,856	not evaluable
Severe congenital heart defect		0.87 [0.25, 3.03]	0%	2 studies	739	1,311	not evaluable
Abdominal wall defects		5.44 [2.63, 11.23]	0%	2 studies	933	1,736	not evaluable
Ear, face and neck anomalies		0.58 [0.08, 4.33]	0%	2 studies	912	1,736	not evaluable
Nervous system anomalies		2.85 [1.39, 5.87]	0%	2 studies	5,852	1,282	not evaluable
Syndromes and chromosomal abnormalities		1.16 [0.62, 2.17]	0%	2 studies	5,553	1,736	not evaluable
Cardiac septal defects		1.87 [1.14, 3.06]	-	1 study		1,097	not evaluable
Other congenital malformations (Q80-84)		2.32 [0.38, 14.27]	50%	2 studies	2,022	1,736	not evaluable
Omphalocele		11.60 [3.61, 37.27]	0%	2 studies	160	1,311	not evaluable
Situs inversus		5.49 [0.58, 51.80]	0%	2 studies	25	1,311	not evaluable
Aplasia cutis congenita		23.36 [1.33, 409.42]	-	1 study	7	1,231	not evaluable
Choanal atresia		25.89 [7.52, 89.13]	0%	2 studies	119	92	not evaluable
30 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	Verdict	OR 95%CI	I2	k	No. cases	No. exposed	publication bias
preterm (< 37 weeks)		1.21 [0.65, 2.23]	0%	4 studies	184	227	not evaluable
low birth weight (< 2500g)		1.60 [0.46, 5.51]	25%	2 studies	141	80	not evaluable
1 non statistically significant endpoints reported in only one study
Maternal consequences
Adverse outcome	Verdict	OR 95%CI	I2	k	No. cases	No. exposed	publication bias
Caesarean		-	-	0 study
3 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	Verdict	OR 95%CI	I2	k	No. cases	No. exposed	publication bias
Goiter		0.96 [0.20, 4.60]	0%	3 studies	6	61	not evaluable
Hypothyroidism (fetal/neonatal)		0.88 [0.10, 7.50]	0%	3 studies	1	54	not evaluable
Hyperthyroidism / Thyrotoxicosis (fetal/neonatal)		0.77 [0.06, 9.94]	0%	2 studies	1	18	not evaluable
2 non statistically significant endpoints reported in only one study
Long term consequences
Adverse outcome	Verdict	OR 95%CI	I2	k	No. cases	No. exposed	publication bias
Neuro-developmental disorders		5.34 [2.17, 13.10]	-	1 study	692	20	not evaluable
Intrauterine deaths
Adverse outcome	Verdict	OR 95%CI	I2	k	No. cases	No. exposed	publication bias
Elective termination of pregnancy		3.39 [1.80, 6.37]	0%	2 studies	46	1,550	not evaluable
Perinatal death		0.70 [0.25, 1.94]	0%	2 studies	16	1,550	not evaluable
Early intrauterine death (< 22 weeks)		3.94 [0.70, 22.25]	93%	2 studies	332	1,654	not evaluable
Intrauterine deaths (as a whole)		1.97 [0.89, 4.35]	0%	2 studies	26	131	not evaluable